Morgan Stanley raised its price target for Neurocrine Biosciences stock, a company that develops treatments for Huntington's chorea.

7 reports, 2 independent Updated Sep 11

Gone quiet

Reports: 7
Developments: 1
Repetition: 86%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Morgan Stanley raised its price target for Neurocrine Biosciences stock, a company that develops treatments for Huntington's chorea.

Who's involved

What this event is mainly about

Neurocrine Biosciences Morgan Stanley

Keep exploring

Part of

Neurocrine Biosciences and Catalyst Pharmaceutical are being considered for value stock investment. All 1 developments

The entities involved

Neurocrine Biosciences
American biopharmaceutical company

Nothing else this week.
Morgan Stanley
U.S. investment bank
- Financial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Mon 17:33
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24

Related events

Nxera Pharma has acquired rights to NBI-’567 through Neurocrine Biosciences, with the goal of improving patient outcomes in Japan.Aug 26

Coverage

Newest first; wire copies grouped

Jul 17dailypolitical.com
Jul 27Insider MonkeyNeurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the 11 Best Long Term Low Risk Stocks to Invest in. Following t

5 more outlets ran the same wire story